JŠJan Šoupal

Jan Šoupal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Šoupal has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond the CE Mark: A Call to Action for Minimum CGM Accuracy Standards in Central and Eastern European Nations

    by Tomasz Klupa, Silvija Canecki‐Varžić, Adriana Ilavská, Andrej Janez, Sanja Klobučar, Mladen Krnić, Tatjana Milenkovic, Peter Novodvorský, Martin Prázný, Marko Simunovic, et al.

  • Open Access

    Switch of Open-Source Automated Insulin Delivery (AID) System—AndroidAPS to Commercially Available AID Systems in Type 1 Diabetes: The Extension of the CODIAC Study

    by Quoc Dat Do, Lucie Radovnická, Aneta Hásková, Judita Konečná, Eva Horová, George Grunberger, Martin Prázný, Christopher G. Parkin, Milan Flekač, Jan Šoupal

    Objective: This study was designed to investigate the switch between the open-source automated insulin delivery (OS-AID) system AndroidAPS (AAPS) and commercially available AID systems Control-IQ (CIQ) and MiniMed 780G (780G) conducted in a new extended follow-up study. Research Design and Methods: In this prospective open-label single-arm clinical trial, 41 adults with type 1 diabetes (age 35 ± 11 years, glycated hemoglobin [HbA1c] 6.4 ± 2.8% [46 ± 6.8 mmol/mol]) who have voluntarily used AAPS entered a total of three study phases. In the first phase, participants continued with AAPS for 3 months. In the second 3-month study phase, all participants initiated CIQ ( n = 25) or 780G ( n = 16). Finally, participants were switched back to the AAPS for the last 3 months phase. Results of the treatment with commercially available AID systems were compared with both AAPS phases. Results: Commercially available systems were comparable to AAPS in achieving time in range (TIR) (84.2 ± 7.6 vs. 85 ± 6.9%; P = 0.31) and in HbA1c (6.4 ± 3 vs. 6.3 ± 2.7% [46 ± 8.8 vs. 45.7 ± 6.2 mmol/mol]; P = 0.68). In contrast, time in tight range (TITR) was significantly higher in AAPS (66.38 ± 11.84 vs. 63.4 ± 11.77, P = 0.035). However, the time in hypoglycemia P < 0.001). These results were consistent after switching back to AAPS. Conclusion: The extension of the Comparison of Different Hybrid Closed-Loop Systems—AndroidAPS and Control-IQ—in adults with Type 1 Diabetes study is the only prospective study to investigate switching between OS and commercially available AID systems. The switch from AAPS to commercially available systems was not associated with a change in TIR. However, the use of AAPS was associated with a higher TITR, but also with a higher risk of hypoglycemia.


  • Open Access

    Blood pressure levels are higher in individuals with type 1 diabetes mellitus compared to healthy subjects during exercise stress test

    by Ondřej Mikeš, Martin Prázný, Jan Šoupal, Josef Marek, Martin Matoulek, Vladimír Tuka

    Type 1 diabetes mellitus (T1DM) is a chronic disease that usually manifests at a younger age and is associated with higher morbidity and mortality compared to the general population. The objective of this study was to assess the blood pressure response to exercise in patients with T1DM with varying durations of diabetes and with respect to the determinants of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during the exercise stress test. This cross-sectional exploratory study included 52 patients (35 with T1DM aged < 35 years and 17 aged > 35 years) and 25 control subjects. All participants were untrained and underwent a cardiopulmonary exercise stress test using a cycle ergometer and their BP was measured manually. Compared to control subjects, both younger and older patients with T1DM had higher SBP and DBP at submaximal exercise load 0,5 W/kg (SBP 124 ± 18; 142 ± 17; 146 ± 19 mmHg, p = 0.0004, respectively, and DBP 75 ± 10; 84 ± 7; 82 ± 7 mmHg, p = 0.0015, respectively), and at peak exercise (SBP 170 ± 24; 188 ± 26; 192 ± 23 mmHg, p = 0.0006, respectively. BP during exercise in T1DM patients in multivariate model was influenced by resting SBP, and diabetes duration. Patients with T1DM exhibited impaired BP control during exercise, which may serve as an early marker of heightened cardiovascular risk.


  • Open Access

    A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective

    by Johan Jendle, Peter Adolfsson, Pratik Choudhary, Klemen Dovc, Alexander Fleming, David C. Klonoff, Julia K. Mader, Nick Oliver, Jennifer L. Sherr, Jan Šoupal, et al.

    People living with diabetes have many medical devices available to assist with disease management. A critical aspect that must be considered is how systems for continuous glucose monitoring and insulin pumps communicate with each other and how the data generated by these devices can be downloaded, integrated, presented and used. Not only is interoperability associated with practical challenges, but also devices must adhere to all aspects of regulatory and legal frameworks. Key issues around interoperability in terms of data ownership, privacy and the limitations of interoperability include where the responsibility/liability for device and data interoperability lies and the need for standard data-sharing protocols to allow the seamless integration of data from different sources. There is a need for standardised protocols for the open and transparent handling of data and secure integration of data into electronic health records. Here, we discuss the current status of interoperability in medical devices and data used in diabetes therapy, as well as regulatory and legal issues surrounding both device and data interoperability, focusing on Europe (including the UK) and the USA. We also discuss a potential future landscape in which a clear and transparent framework for interoperability and data handling also fulfils the needs of people living with diabetes and healthcare professionals. Graphical Abstract


  • Open Access

    Comparison of Control‐IQ and open‐source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study

    by Quoc Dat Do, Aneta Hásková, Lucie Radovnická, Judita Konečná, Eva Horová, Christopher G. Parkin, George Grunberger, Martin Prázný, Jan Šoupal

    Aim: To compare open‐source AndroidAPS (AAPS) and commercially available Control‐IQ (CIQ) automated insulin delivery (AID) systems in a prospective, open‐label, single‐arm clinical trial. Methods: Adults with type 1 diabetes who had been using AAPS by their own decision entered the first 3‐month AAPS phase then were switched to CIQ for 3 months. The results of this treatment were compared with those after the 3‐month AAPS phase. The primary endpoint was the change in time in range (% TIR; 70‐80 mg/dL). Results: Twenty‐five people with diabetes (mean age 34.32 ± 11.07 years; HbA1c 6.4% ± 3%) participated in this study. CIQ was comparable with AAPS in achieving TIR (85.72% ± 7.64% vs. 84.24% ± 8.46%; P = .12). Similarly, there were no differences in percentage time above range (> 180 and > 250 mg/dL), mean sensor glucose (130.3 ± 13.9 vs. 128.3 ± 16.9 mg/dL; P = .21) or HbA1c (6.3% ± 2.1% vs. 6.4% ± 3.1%; P = .59). Percentage time below range (< 70 and < 54 mg/dL) was significantly lower using CIQ than AAPS. Even although participants were mostly satisfied with CIQ (63.6% mostly agreed, 9.1% strongly agreed), they did not plan to switch to CIQ. Conclusions: The CODIAC study is the first prospective study investigating the switch between open‐source and commercially available AID systems. CIQ and AAPS were comparable in achieving TIR. However, hypoglycaemia was significantly lower with CIQ.


  • Open Access

    Low Initial Adherence with Flash Glucose Monitoring is Not a Predictor of Long-Term Glycemic Outcomes: Longitudinal Analysis of the Association Between Experience, Adherence, and Glucose Control for FreeStyle Libre Users

    by Jan Šoupal, Kalvin Kao, Laura Brandner, George Grunberger, Martin Prázný

    Introduction Frequent scanning of FreeStyle Libre (FSL) flash glucose monitoring sensors is known to be important whilst wearing an active sensor, but adherence to sensor reapplication is also critical to effective glucose monitoring. We report novel measures of adherence for users of the FSL system and their association with improvements in metrics of glucose control. Methods Anonymous data were extracted for 1600 FSL users in the Czech Republic with ≥ 36 completed sensors from October 22, 2018 to December 31, 2021. “Experience” was defined by the number of sensors used (1–36 sensors). “Adherence” was defined by time between the end of one sensor and the start of the next (gap time). User adherence was analyzed for four experience levels after initiating FLASH; Start (sensors 1–3); Early (sensors 4–6); Middle (sensors 19–21); End (sensors 34–36). Users were split into two adherence levels based on mean gap time during Start period, “low” (> 24 h, n = 723) and “high” (≤ 8 h, n = 877). Results Low-adherence users reduced their sensor gap times significantly: 38.5% applied a new sensor within 24 h during sensors 4–6, rising to 65.0% by sensors 34–36 (p < 0.001). Improved adherence was associated with increased %TIR (time in range; mean + 2.4%; p < 0.001), reduced %TAR (time above range; mean − 3.1%; p < 0.001), and reduced glucose coefficient of variation (CV; mean − 1.7%; p < 0.001). Conclusions With experience, FSL users became more adherent in sensor reapplication, with associated increases in %TIR, and reductions in %TAR and glucose variability.


  • Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial

    by Aneta Hásková, Lucie Radovnická, Lenka Petruželková, Christopher G. Parkin, George Grunberger, Eva Horová, Vendula Navrátilová, Ondřej Kádě, Martin Matoulek, Martin Prázný, et al.

    OBJECTIVE The aim of this trial was to compare the efficacy of real-time and intermittently scanned continuous glucose monitoring (rtCGM and isCGM, respectively) in maintaining optimal glycemic control. RESEARCH DESIGN AND METHODS In this randomized study, adults with type 1 diabetes (T1D) and normal hypoglycemia awareness (Gold score n = 30) or isCGM (n = 30). All participants completed the study. Percentage of time in hypoglycemia (P = 0.018) and during the home phase (5.3 ± 2.5% vs. 7.3 ± 4.4%, respectively; P = 0.035). Hypoglycemia differences were significant and most notable during the night. rtCGM participants spent more time in range (3.9–10 mmol/L [70–180 mg/dL]) than isCGM participants throughout both the exercise (78.5 ± 10.2% vs. 69.7 ± 16%, respectively; P = 0.0149) and home (75.6 ± 9.7% vs. 67.4 ± 17.8%, respectively; P = 0.0339) phases. The results were robust to the insignificant bias between rtCGM and isCGM sensors that masked CGM found in the isCGM arm. CONCLUSIONS rtCGM was superior to isCGM in reducing hypoglycemia and improving time in range in adults with T1D with normal hypoglycemia awareness, demonstrating the value of rtCGM alarms during exercise and in daily diabetes self-management.


  • Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study

    by Jan Šoupal, Lenka Petruželková, George Grunberger, Aneta Hásková, Milan Flekač, Martin Matoulek, Ondřej Mikeš, Tomáš Pelcl, Jan Škrha, Eva Horová, et al.

    OBJECTIVE This study assessed the clinical impact of four treatment strategies in adults with type 1 diabetes (T1D): real-time continuous glucose monitoring (rtCGM) with multiple daily insulin injections (rtCGM+MDI), rtCGM with continuous subcutaneous insulin infusion (rtCGM+CSII), self-monitoring of blood glucose with MDI (SMBG+MDI), and SMBG with CSII (SMBG+CSII). RESEARCH DESIGN AND METHODS This 3-year, nonrandomized, prospective, real-world, clinical trial followed 94 participants with T1D (rtCGM+MDI, n = 22; rtCGM+CSII, n = 26; SMBG+MDI, n = 21; SMBG+CSII, n = 25). The main end points were changes in A1C, time in range (70–180 mg/dL [3.9–10 mmol/L]), time below range (P = 0.0002, and 6.9% [52 mmol/mol], P < 0.0001, respectively), compared with the SMBG+CSII and SMBG+MDI groups (7.7% [61 mmol/mol], P = 0.3574, and 8.0% [64 mmol/mol], P = 1.000, respectively), with no significant difference between the rtCGM groups. Significant improvements in percentage of time in range were observed in the rtCGM subgroups (rtCGM+MDI, 48.7–69.0%, P < 0.0001; and rtCGM+CSII, 50.9–72.3%, P < 0.0001) and in the SMBG+CSII group (50.6–57.8%, P = 0.0114). Significant reductions in time below range were found only in the rtCGM subgroups (rtCGM+MDI, 9.4–5.5%, P = 0.0387; and rtCGM+CSII, 9.0–5.3%, P = 0.0235). Seven severe hypoglycemia episodes occurred: SMBG groups, n = 5; sensor-augmented insulin regimen groups, n = 2. CONCLUSIONS rtCGM was superior to SMBG in reducing A1C, hypoglycemia, and other end points in individuals with T1D regardless of their insulin delivery method. rtCGM+MDI can be considered an equivalent but lower-cost alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy.